PTGS2 and neoplasm: Clinically, selective COX-2 inhibitors such as celecoxib have demonstrated chemopreventive and therapeutic benefits: long-term use is associated with reduced incidence of colorectal, lung, esophageal, and hepatic malignancies, while adjuvant administration enhances response to cytotoxic chemotherapy by sensitizing tumor cells to apoptosis.